STOCKWATCH: The death of surrogate markers
This article was originally published in Scrip
Over the past week investors have had cause to rue the vain attempts by some biotechnology companies to get their drugs approved on the basis of indirect markers of disease which are not clinical or functional – the so-called surrogate endpoints. The surrogate endpoint debate is coming back to bite those who have invested in companies whose management teams prefer to pay themselves big bucks, rather than spend money on a definitive Phase II or Phase III clinical trial. The FDA also seems to be going cold on accelerated approvals based on surrogate endpoints.
You may also be interested in...
AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.
The prices of biotechnology and pharmaceutical sector indices continue to be comparatively robust in the face of big falls in global markets as investors expect new drugs and vaccines to be generated by the sector. While it is largely accepted that the life science sector will eventually ride to the rescue, bumper profits are far from guaranteed.
Pharmaceutical shares are stronger than most as world stock markets dive downwards, but they are not immune to the coronavirus fallout. The effects will be felt by biopharma companies across many areas of their activity.